Aclaris Therapeutics, Inc. (ACRS) Free cash flow 2016–2025
Aclaris Therapeutics, Inc. (ACRS) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$47.2MFY2025 · since FY2016: -$34.8M → -$47.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$47.2M | -133.8% |
| FY2024 | -$20.2M | +74.6% |
| FY2023 | -$79.6M | -16.8% |
| FY2022 | -$68.2M | -30.0% |
| FY2021 | -$52.4M | -34.2% |
| FY2020 | -$39.1M | +60.1% |
| FY2019 | -$98.1M | +4.0% |
| FY2018 | -$102.2M | -82.8% |
| FY2017 | -$55.9M | -60.5% |
| FY2016 | -$34.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice